bimatoprost
Latisse · Lumigan
1 INDICATIONS AND USAGE Bimatoprost ophthalmic solution 0.03% is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. Bimatoprost ophthalmic solution 0.03% is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. ( 1 )
Mechanism. 12.1 Mechanism of Action Bimatoprost, a prostaglandin analog, is a synthetic structural analog of prostaglandin with ocular hypotensive activity. It selectively mimics the effects of naturally occurring substances, prostamides. Bimatoprost is believed to lower intraocular pressure (IOP) in humans by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes. Elevated IOP presents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.
What stands out in the reports.
ROR = reporting odds ratio (log scale). A value above 1 means the symptom is reported more often for this product than for all other products combined. This measures how much it stands out in reports — not cause, not risk.
Bimatoprost, used for eyelash growth and glaucoma, shows disproportionately reported adverse effects. "Blepharal pigmentation" (eyelid darkening) and "growth of eyelashes" are very frequently reported. This is logical, as bimatoprost is known to affect pigment and hair follicles. "Increased lacrimation" (tearing) and "increased intraocular pressure" are also more often reported, which aligns with its eye-related actions. Remember, "frequently reported" doesn't mean bimatoprost "frequently causes" these effects. This does not replace medical advice.
This does not replace medical advice.
No signals currently mapped to the label.
Report volume per quarter.
| Date | Class | Reason | Firm |
|---|---|---|---|
| Oct 19, 2017 | III | Failed Impurities/Degradation Specifications. | Allergan Sales, LLC |
| Mar 16, 2017 | III | Failed Impurities/Degradation Specifications | Allergan Sales, LLC |
Class I = reasonable probability of serious harm · Class II = temporary or reversible · Class III = unlikely to cause harm. Source: openFDA enforcement.